...So, good morning, everyone, and thank you for attending Citi's 16th Annual Biopharma Conference. I'm Neena Bitritto-Garg. I'm one of the biotech analysts here, if you don't know me. And for our next session, I'm really pleased to be joined this morning by leadership from three companies developing drugs in the psychiatric disease and broader CNS space as well: Cerevel, Karuna and Praxis Precision Medicines. So, from Cerevel, we have CMO, Ray Sanchez; from Karuna, we have Steve Paul, CEO; and from Praxis, we have Marcio Souza, CEO as well. And we'll cover some high-level topics this morning in psychiatry; some specific indications, including schizophrenia, DRP and depression; and some specific programs that each of you are developing as well. Before we get into the discussion, I just wanted to remind the listeners that if you do have a question, feel free to e-mail me directly or you can actually submit questions here at online portal and I'll receive them as well and I'll try to incorporate...